Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Robert McWhirter commented about whether BB.TO, CGY.TO, DVQ.TO, VSM.TO, CMH.TO, LTV.TO, EME-T-DEAD, IDL.V, CIC.TO, OTEX.TO, NTEL.TO, BDGI.TO, CMG.TO, CRYP, XLX.TO, HP.TO, MTM.H.TO are stocks to buy or sell.

DON'T BUY
Dramatically tied to Nortel's performance which is why their shares pulled back substantially. In the bottom 1/3 of their database. Earnings estimates have been pulled back.
DON'T BUY
In the bottom 15% of their database. Have restated earnings. Earnings estimates have dropped by about 11% over the last 90 days.
DON'T BUY
In the bottom 20% of their database. Moving ahead with FDA testing. Still expected to lose six cents in 2004. Should see improvement in four months.
BUY
In the top 15% of their database. Year-over-year earnings growth is up 56% on an increase of sales of 40%. Continuing to diversify away from the US.
WEAK BUY
Products are sold globally and having good acceptance. Should have reasonable return over the next two years, but they prefer others.
PAST TOP PICK
(A top pick Feb 12/04. Up 3%.) Feels there is still very strong growth opportunities. Ranks in the top 10% of the database.
PAST TOP PICK
(A top pick Feb 12/04. Down 48%.)
TOP PICK
(A top pick Feb 12/04. Down 3%.) Still very good opportunities/outlook for it. Ranks in the top 20% of the database. In the last quarter, an earnings surprise of 16% and sales were up 45% and earnings up 53%.
DON'T BUY
Ranks borderline in the top 1/3 of their database. Expected to lose $0.04 out to April/05. Moving towards an intellectual property model based on their patents. Fully valued.
DON'T BUY
There is a raging debate going on amongst the analysts. Have hired a significant amount of new salespeople. Feels earnings will be less.
DON'T BUY
Stock dropped when BCE sold their shares. The question is, can management turnaround the existing businesses to get you a reasonable return on equity. Changes of management have not been able to deliver.
WATCH
Ranks borderline in the top 1/4 of their database. Earnings estimates have gone up by about 20%. Year-over-year sales are down 32%. New management is well respected.
HOLD
Have some interesting contracts going on in Europe. Outlook is good. Fully priced.
DON'T BUY
Earnings estimates have been chopped by 95% in the last three months. Earnings are expected to improve. Too expensive.
BUY
Analysts are forecasting earnings of $.10 in the current calendar year. Strong outlook for the company. Stock is cheap.